Seeking Alpha

Pavmed adds to EsoGuard-stoked rally, up 18%

|About: PAVmed Inc. (PAVM)|By: , SA News Editor

Nano cap PAVmed (PAVM +17.8%) is up on triple normal volume. Shares have jumped 60% in less than a month after it announced the availability of its EsoGuard Esophageal DNA Test (offered as a service at an Irvine, CA lab). The test is designed to aid in the diagnosis of Barrett's esophagus (complication of gastroesophageal reflux disease) and related precursors to esophageal adenocarcinoma.